Cargando…

Freund's vaccine adjuvant promotes Her2/Neu breast cancer

BACKGROUND: Inflammation has been linked to the etiology of many organ-specific cancers. Indirect evidence suggests a possible role for inflammation in breast cancer. We investigated whether the systemic inflammation induced by Freund's adjuvant (FA) promotes mammary carcinogenesis in a rat mod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cotroneo, Michelle S, Haag, Jill D, Stapel, Nicholas R, Waller, Jordy L, Woditschka, Stephan, Gould, Michael N
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2633343/ https://www.ncbi.nlm.nih.gov/pubmed/19144184 http://dx.doi.org/10.1186/1471-2407-9-19

Ejemplares similares

Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model
por: Woditschka, Stephan, et al.
Publicado: (2008)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer
por: James, Rani, et al.
Publicado: (2011)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

Mannosylated T/Tn with Freund’s adjuvant induces cellular immunity
por: Son, Hye-Youn, et al.
Publicado: (2017)

Vaccination against Her-2/neu, with focus on peptide-based vaccines
por: Tobias, J., et al.
Publicado: (2022)

The non-protein coding breast cancer susceptibility locus Mcs5a acts in a non-mammary cell-autonomous fashion through the immune system and modulates T-cell homeostasis and functions
por: Smits, Bart MG, et al.
Publicado: (2011)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide
por: Tobias, Joshua, et al.
Publicado: (2017)

Effect of Losartan in Complete Freund’s Adjuvant –Induced Arthritis in Rats
por: Abdel El- Gaphar, Omnia Ahmed Mohamed, et al.
Publicado: (2018)

Synthetic mycobacterial molecular patterns partially complete Freund’s adjuvant
por: Dubé, Jean-Yves, et al.
Publicado: (2020)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Cell Recruitment and Cytokines in Skin Mice Sensitized with the Vaccine Adjuvants: Saponin, Incomplete Freund’s Adjuvant, and Monophosphoryl Lipid A
por: Vitoriano-Souza, Juliana, et al.
Publicado: (2012)

Reproducibility in the automated quantitative assessment of HER2/neu for breast cancer
por: Keay, Tyler, et al.
Publicado: (2013)

Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model
por: Tobias, Joshua, et al.
Publicado: (2022)

Induction of progressive nephropathy in rats by eluted gamma-globulin and Freund's adjuvant.
por: Nagi, A. H.
Publicado: (1971)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Prime–boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu(+ )metastatic breast cancer in mice
por: Wang, Xiaoyan, et al.
Publicado: (2005)

Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors
por: Flågeng, M Hauglid, et al.
Publicado: (2009)

Efficacy and Safety of Native and Recombinant Zona Pellucida Immunocontraceptive Vaccines Formulated with Non-Freund’s Adjuvants in Donkeys
por: French, Hilari, et al.
Publicado: (2022)

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R
por: De Giovanni, Carla, et al.
Publicado: (2019)

HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma
por: Liu, Tieju, et al.
Publicado: (2013)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni, Mohamad Adham, et al.
Publicado: (2021)

Effect of Trichilia monadelpha (Meliaceae) extracts on bone histomorphology in complete Freund’s adjuvant-induced arthritis
por: Ben, Inemesit Okon, et al.
Publicado: (2017)

Does HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey
por: Myers, J.A., et al.
Publicado: (2006)

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial
por: Rodenhuis, S, et al.
Publicado: (2005)

Mixed Adjuvant Formulations Reveal a New Combination That Elicit Antibody Response Comparable to Freund's Adjuvants
por: Lai, Rachel P. J., et al.
Publicado: (2012)

Further Observations on the Results of Combining Freund's Adjuvant with Living Ehrlich Ascites Carcinoma
por: Hartveit, F.
Publicado: (1962)

Thymic stromal lymphopoietin is a key cytokine for the immunomodulation of atherogenesis with Freund's adjuvant
por: Steinmetz, Martin, et al.
Publicado: (2020)

The effect of orofacial complete Freund’s adjuvant treatment on the expression of migraine-related molecules
por: Körtési, Tamás, et al.
Publicado: (2019)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

A Novel Interaction Between HER2/neu and Cyclin E in Breast Cancer
por: Mittendorf, Elizabeth A., et al.
Publicado: (2010)

Status of HER-2/neu receptors and Ki-67 in breast cancer of Indian women
por: Singhai, Rajeev, et al.
Publicado: (2011)

Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer
por: Shukla, Shailaja, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_b01bg9aonoqh7d8hk133m4sgou